Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
9P - Mesenchymal stem cells’ microvesicles from primary and metastatic NSCLC niches differentially modulate lung cancer cells (ID 160)
12:30 - 13:00 | Author(s): L. Drucker
Novel therapeutic approaches are urgently needed in lung cancer, particularly ones that address the malignant cells in their stroma microenvironment critical to drug resistance and disease relapse. The stroma constituents, mesenchymal stem cells (MSCs), interact with cancer cells by various methods including transfer of microvesicles (MVs) that vehicle protein, mRNA and microRNAs thereby altering recipient cells’ phenotype. Here, we examined the effect of MSCs’ MVs from primary (lung) and metastatic (bone marrow (BM)) niches on NSCLC cells with emphasis on translation initiation's (TI) role in the process.
Lung and BM MSCs’ MVs were isolated and applied to NSCLC cell lines (H1299, H460). MVs uptake was confirmed and NSCLC cells were assayed for: viability (WST-1); cell count/death (trypan); proliferation (PCNA); migration (scratch); autophagy; TI status (factors, regulators, targets); MAPKs activation (immunoblotting).
We observed increased viability, proliferation and migration of Lung-MSCs’ MVs treated NSCLC cells whereas, BM-MSCs’ MVs treated cells showed reductions (50–90% and −40%, respectively p < 0.05). Correspondingly, Lung MSCs’ MVs elevated TI status whereas BM-MSCs’ MVs diminished it (60–120% and −30–70%, respectively p < 0.05). The opposite trend was also evident in MAPK activation and autophagy induction.
Our observations not only depict a role for MSCs’ MVs in NSCLC phenotype but also display distinct differences between the primary and metastatic niches and may emphasize specific factors that shape disease progression. Further studies into the mechanism underlying the MVs-NSCLC cells’ contact and cargo transfer may promote the design of a therapeutic approach that will sabotage the dialogue between NSCLC cells and MSCs.
Clinical trial identification:
Legal entity responsible for the study:
Meir Medical Center
Has not received any funding
All authors have declared no conflicts of interest.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.